Critical Survey: Arch Therapeutics (OTCMKTS: ARTH) vs. Lucid Diagnostics (NASDAQ: LUCD)

Arch Therapeutics (OTCMKTS:ARTH – Get Rating) and Lucid Diagnostics (NASDAQ:LUCD – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on their risk strength, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Institutional and Insider Ownership

8.9% of Arch Therapeutics shares are held by institutional investors. By comparison, 8.8% of shares in Lucid Diagnostics are held by institutional investors. 12.2% of Arch Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds, and large money managers believe a company is poised for long-term growth.

Valuation and benefits

This table compares the revenue, earnings per share (EPS), and valuation of Arch Therapeutics and Lucid Diagnostics.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Therapeutic Arc $10,000.00 1,043.96 -$6.24 million N / A N / A
Clear diagnoses $500,000.00 199.53 -$28.08 million N / A N / A

Arch Therapeutics has higher revenue, but lower revenue than Lucid Diagnostics.


This table compares the net margins, return on equity and return on assets of Arch Therapeutics and Lucid Diagnostics.

Net margins Return on equity return on assets
Therapeutic Arc N / A N / A -178.11%
Clear diagnoses N / A N / A N / A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arch Therapeutics and Lucid Diagnostics, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Therapeutic Arc 0 0 0 0 N / A
Clear diagnoses 0 0 6 0 3.00

Lucid Diagnostics has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Lucid Diagnostics’ possible higher upside, analysts clearly believe that Lucid Diagnostics is more favorable than Arch Therapeutics.

About Arch Therapeutics

(Get an assessment)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembly technology platform to stop bleeding and control leakage, as well as to manage wounds during surgery, trauma, and interventional or disease care. Its flagship products include AC5 Advanced Wound Care System and AC5 Topical Hemostat, which are intended for cutaneous applications, such as the management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

About Lucid Diagnoses

(Get an assessment)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostic technology company. The company is focused on patients with gastroesophageal reflux, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, particularly a highly lethal esophageal adenocarcinoma. Its main products include EsoGuard, a laboratory-developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Get news and reviews for Arch Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Arch Therapeutics and related companies with’s free daily email newsletter.